How to use dialysis wisely in cancer patients?

Author:

van der Veen Annelien1,De Vusser Katrien1,De Moor Bart23,Wildiers Hans45,Cosmai Laura6,Sprangers Ben178ORCID

Affiliation:

1. Department of Nephrology, University Hospitals Leuven, Leuven, Belgium

2. Department of Nephrology, Jessa Hospital of Hasselt, Hasselt, Belgium

3. Faculty of Medicine and Life Sciences, University of Hasselt, Diepenbeek, Belgium

4. Department of Oncology, KU Leuven, Belgium

5. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

6. Onco-Nephrology Clinic, Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, ASST Santi Carlo e Paolo, Milan, Italy

7. Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Belgium

8. Cancer-Kidney International Network (C-KIN), Brussels, Belgium

Abstract

Both acute kidney injury (AKI) and chronic kidney disease (CKD) are common in cancer patients and are associated with inferior outcome, higher mortality rates, longer hospital stays and higher costs. In the aging population, the prevalence of both cancer and end-stage renal disease increase and practitioners are faced with difficult decisions regarding initiation of anticancer therapy and renal replacement therapy (RRT). Recent studies have shown no survival benefit of RRT ⩾80 years or even ⩾70 years in combination with severe comorbidities. However cancer itself does not seem to be a determining factor for short-term survival outcome and should not be used as argument alone to withhold RRT. Several prognostic tools can be implemented to identify elderly patients at high risk of functional decline and mortality after initiation of RRT. Advanced care planning focusses on timely discussions between patients, family members and practitioners about the patient’s desires and treatment goals which can help them avoid decisional conflict at the end-of-life and improve the quality of life.

Publisher

SAGE Publications

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3